3.0T磁共振多参数成像及动态增强扫描对前列腺癌的诊断价值

目的探讨3.0T磁共振多参数成像及动态增强扫描定性及半定量参数在前列腺疾病诊断中的价值。方法回顾性分析我院2017年6月至2021年6月经病理证实的98例前列腺疾病患者的临床及影像学资料,其中前列腺癌(PCa)38例,前列腺增生(BPH)60例。观察并分析各个病灶的影像学特点、绘制SI-T曲线并计算动态增强扫描半定量参数值及其诊断效能。结果双参数、多参数磁共振成像对诊断PCa的准确率分别为86.73%、95.92%,多参数成像优于双参数成像;PCa组SI-T曲线以速升缓降型为主,BPH组以持续缓升型及缓升平台型为主。两组患者的SI-T曲线类型比较,差异有统计学意义(P<0.05);PCa/BPH的半定量值中,除了SI_max%组间差异无统计学意义(P>0.05),其他组间差异均有统计学意义(P<0.001)。ROC曲线示:T_max对于鉴别前列腺良恶性疾病效能最佳(AUC=0.885)。结论多参数磁共振成像及动态增强扫描在诊断前列腺疾病中有重要临床价值。

Diagnostic Value of 3.0T MR Multiparameter Imaging and Dynamic Contrast-Enhanced Scanning in Prostate Cancer

Objective To explore the value of 3.0T magnetic resonance multiparameter imaging and qualitative and semi-quantitative parameters of dynamic contrast-enhanced scanning in the diagnosis of prostate diseases.Methods The clinical and imaging data of 98 patients with prostate diseases confirmed by pathology in our hospital from June 2017 to June 2021 were analyzed retrospectively,including 38 cases of prostate cancer(PCA)and 60 cases of benign prostatic hyperplasia(BPH).The imaging characteristics of each lesion were observed and analyzed,the SI-T curve was drawn,and the semi-quantitative parameters and diagnostic efficiency of dynamic contrast-enhanced scanning were calculated.Results The accuracy of dual parameter and multi parameter MRI in the diagnosis of PCA was 86.73%,95.92%respectively;The SI-T curve of PCA group was mainly of rapid rise and slow fall type,and that of BPH group was mainly of continuous slow rise type and slow rise platform type.There was significant difference in SI-T curve types between the two groups(P<0.05);In the semi quantitative value of PCA/BPH,except for SI_max%,there was no significant difference between groups(P>0.05),there were significant differences among other groups(all P<0.001).ROC curve shows that T_max is the best for differentiating benign and malignant prostate diseases(AUC=0.885).Conclusion Multiparameter magnetic resonance imaging and dynamic contrast-enhanced scanning have important clinical value in the diagnosis of prostate diseases.